RIPK3 and Hyperammonemia: In addition to inhibiting RIPK1 and RIPK3, inhibition of the TLR4 pathway by TAK-242 or TLR4 deficiency was found to significantly reduce circulating ammonia levels, which was validated in clinically relevant models of hyperammonemia due to cirrhosis or UCD.